Active — Not RecruitingNot Applicable

International Alfapump Cohort Study

Germany, Switzerland400 participantsStarted 2018-08-14

Plain-language summary

This Registry is designed to follow patients who have been implanted with an alfapump system, which is a newly marketed product from Sequana Medical AG, a Swiss Medical Device company.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All patients implanted with an alfapump are eligible for this registry Exclusion Criteria: * Patients younger than 18 years * Pregnancy * Inability to operate the Smart Charger to recharge the alfapump * Participating in another study in which the alfapump is studied

What they're measuring

Patient survival at 6 months post implant

Timeframe: 6 months post-implant

Trial details

NCT IDNCT04326946

SponsorSequana Medical N.V.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2028-12-31

View on ClinicalTrials.gov More Liver Cirrhoses trials